Boston Scientific Corporation Company Profile (NYSE:BSX)

About Boston Scientific Corporation (NYSE:BSX)

Boston Scientific Corporation logoBoston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology. It operates in three segments: Cardiovascular, Rhythm Management and MedSurg. Its Cardiovascular segment consists of Interventional Cardiology and Peripheral Interventions businesses. Rhythm Management consists of Cardiac Rhythm Management and Electrophysiology businesses. MedSurg consists of Endoscopy, Urology and Pelvic Health, and Neuromodulation businesses. Its Interventional Cardiology product offerings include balloon catheters, rotational atherectomy systems, guide wires, guide catheters and embolic protection devices and diagnostic catheters used in percutaneous transluminal coronary angioplasty (PTCA) procedures.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Advanced Medical Equipment & Technology
  • Sub-Industry: Health Care Equipment
  • Symbol: NYSE:BSX
  • CUSIP: 10113710
  • Web:
  • Market Cap: $39.35 billion
  • Outstanding Shares: 1,372,127,000
Average Prices:
  • 50 Day Moving Avg: $27.39
  • 200 Day Moving Avg: $26.61
  • 52 Week Range: $19.67 - $29.40
  • Trailing P/E Ratio: 51.61
  • Foreward P/E Ratio: 20.49
  • P/E Growth: 2.13
Sales & Book Value:
  • Annual Revenue: $8.71 billion
  • Price / Sales: 4.52
  • Book Value: $5.28 per share
  • Price / Book: 5.43
  • EBIDTA: $2.31 billion
  • Net Margins: 9.04%
  • Return on Equity: 23.62%
  • Return on Assets: 9.01%
  • Debt-to-Equity Ratio: 0.67%
  • Current Ratio: 0.75%
  • Quick Ratio: 0.51%
  • Average Volume: 5.50 million shs.
  • Beta: 1.09
  • Short Ratio: 1.48

Frequently Asked Questions for Boston Scientific Corporation (NYSE:BSX)

What is Boston Scientific Corporation's stock symbol?

Boston Scientific Corporation trades on the New York Stock Exchange (NYSE) under the ticker symbol "BSX."

How were Boston Scientific Corporation's earnings last quarter?

Boston Scientific Corporation (NYSE:BSX) released its earnings results on Thursday, July, 27th. The company reported $0.32 earnings per share for the quarter, beating the consensus estimate of $0.31 by $0.01. The business had revenue of $2.26 billion for the quarter, compared to the consensus estimate of $2.21 billion. Boston Scientific Corporation had a return on equity of 23.62% and a net margin of 9.04%. The business's quarterly revenue was up 6.2% compared to the same quarter last year. During the same quarter last year, the business posted $0.27 earnings per share. View Boston Scientific Corporation's Earnings History.

When will Boston Scientific Corporation make its next earnings announcement?

Boston Scientific Corporation is scheduled to release their next quarterly earnings announcement on Wednesday, October, 25th 2017. View Earnings Estimates for Boston Scientific Corporation.

What guidance has Boston Scientific Corporation issued on next quarter's earnings?

Boston Scientific Corporation updated its FY17 earnings guidance on Thursday, July, 27th. The company provided earnings per share guidance of $1.23-1.27 for the period, compared to the Thomson Reuters consensus EPS estimate of $1.25. The company issued revenue guidance of $8.89-8.99 billion, compared to the consensus revenue estimate of $8.87 billion.Boston Scientific Corporation also updated its Q3 guidance to $0.29-0.31 EPS.

Where is Boston Scientific Corporation's stock going? Where will Boston Scientific Corporation's stock price be in 2017?

16 equities research analysts have issued 12 month price objectives for Boston Scientific Corporation's shares. Their predictions range from $28.00 to $32.00. On average, they anticipate Boston Scientific Corporation's stock price to reach $30.19 in the next twelve months. View Analyst Ratings for Boston Scientific Corporation.

What are analysts saying about Boston Scientific Corporation stock?

Here are some recent quotes from research analysts about Boston Scientific Corporation stock:

  • 1. Jefferies Group LLC analysts commented, "We are re-establishing estimates, a Buy rating and $14.00 PT for Flex Pharma. Flex is developing FLX-787, an innovative anti-cramp drug in amyotrophic lateral sclerosis (ALS), Charcot-Marie-Tooth disease (CMT) and multiple sclerosis (MS). We believe CMT , on which we base our PT , has the highest chance of success. We anticipate Ph2 data in 1Q’18 (MS) and 3Q’18 (ALS, CMT). In 2Q’16, Flex launched HOTSHOT , a consumer beverage for exercise- associated muscle cramps that works via the same mechanisms as FLX-787." (9/7/2017)
  • 2. According to Zacks Investment Research, "Boston Scientific posted a better-than-expected second quarter, with earnings and revenues both remaining ahead of the Zacks Consensus Estimate. On a positive note, the company is leaving no stone unturned to strengthen its core businesses and invest more in global markets. Among the recent developments, worth mentioning is the company’s acquisition of Symetis, in a bid to fortify its structural heart business in Europe. We are also encouraged with the company gaining a number of product approvals both in the domestic and overseas markets. Notably, the company received an FDA approval for the RESONATE family of ICD and CRT-D systems. Yet, the recent recall of its Lotus range of heart devices hampered sales in the quarter. Also the unimpressive defibrillator performance within the core CRM continues to remain a drag. We are still concerned about the foreign exchange headwind. In general, over the past three months, Boston Scientific is trading below the broader industry." (7/31/2017)
  • 3. Needham & Company LLC analysts commented, "BSX beat consensus 1Q17 revenue but missed consensus EPS due to expense associated with the Lotus withdrawal. Management raised its revenue guidance but maintained its EPS guidance for 2017. BSX’s organic revenue growth slowed slightly to 9% in 1Q17 from 10% in 4Q16 despite facing a more difficult comp. MedSurg growth accelerated and offset slower Cardiovascular growth as BSX lapped the US Synergy launch. Margins were below expectations with BSX’s gross margin down 170 bps Y/Y and operating margin down 210 bps Y/Y but this was mostly due to the impact of the Lotus withdrawal." (4/27/2017)

Who are some of Boston Scientific Corporation's key competitors?

Who are Boston Scientific Corporation's key executives?

Boston Scientific Corporation's management team includes the folowing people:

  • Michael F. Mahoney, Chairman of the Board, President, Chief Executive Officer
  • Daniel J. Brennan, Chief Financial Officer, Executive Vice President
  • Timothy A. Pratt, Chief Administrative Officer, Executive Vice President, General Counsel, Secretary
  • Supratim Bose, Executive Vice President; President, Asia-Pacific, Middle East and Africa
  • Keith D. Dawkins M.D., Global Chief Medical Officer, Executive Vice President
  • Joseph M. Fitzgerald, Executive Vice President; President - Rhythm Management
  • Edward F. Mackey, Executive Vice President - Operations
  • Ian T. Meredith AM, Executive Vice President, Global Chief Medical Officer
  • Michael P. Phalen, Executive Vice President; President - MedSurg
  • Wendy Carruthers, Senior Vice President - Human Resources

Who owns Boston Scientific Corporation stock?

Boston Scientific Corporation's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include FMR LLC (12.72%), Capital World Investors (7.43%), BlackRock Inc. (7.31%), Vanguard Group Inc. (6.83%), State Street Corp (4.17%) and Janus Henderson Group PLC (2.83%). Company insiders that own Boston Scientific Corporation stock include Charles J Dockendorff, Daniel J Brennan, David A Pierce, Ernest Mario, Jeffrey B Mirviss, John Bradley Sorenson, Joseph Michael Fitzgerald, Karen Prange, Keith D Dawkins, Kevin J Ballinger, Maulik Nanavaty, Michael F Mahoney, Michael P Phalen, Timothy A Pratt and Wendy Carruthers. View Institutional Ownership Trends for Boston Scientific Corporation.

Who sold Boston Scientific Corporation stock? Who is selling Boston Scientific Corporation stock?

Boston Scientific Corporation's stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Artisan Partners Limited Partnership, Standard Life Investments LTD, Marshall Wace North America L.P., Arrowstreet Capital Limited Partnership, Gotham Asset Management LLC, Bollard Group LLC and BNP Paribas Arbitrage SA. Company insiders that have sold Boston Scientific Corporation stock in the last year include Daniel J Brennan, David A Pierce, John Bradley Sorenson, Keith D Dawkins, Kevin J Ballinger, Maulik Nanavaty, Michael P Phalen, Timothy A Pratt and Wendy Carruthers. View Insider Buying and Selling for Boston Scientific Corporation.

Who bought Boston Scientific Corporation stock? Who is buying Boston Scientific Corporation stock?

Boston Scientific Corporation's stock was purchased by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Jennison Associates LLC, BlackRock Inc., Los Angeles Capital Management & Equity Research Inc., Vanguard Group Inc., Winslow Capital Management LLC, Capital World Investors and Lord Abbett & CO. LLC. View Insider Buying and Selling for Boston Scientific Corporation.

How do I buy Boston Scientific Corporation stock?

Shares of Boston Scientific Corporation can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Boston Scientific Corporation's stock price today?

One share of Boston Scientific Corporation stock can currently be purchased for approximately $28.68.

MarketBeat Community Rating for Boston Scientific Corporation (NYSE BSX)
Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  536 (Vote Outperform)
Underperform Votes:  512 (Vote Underperform)
Total Votes:  1,048
MarketBeat's community ratings are surveys of what our community members think about Boston Scientific Corporation and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Boston Scientific Corporation (NYSE:BSX) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 4 Hold Ratings, 12 Buy Ratings
Consensus Rating:Buy (Score: 2.75)
Consensus Price Target: $30.19 (5.27% upside)

Analysts' Ratings History for Boston Scientific Corporation (NYSE:BSX)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
9/7/2017Jefferies Group LLCReiterated RatingHoldLowView Rating Details
9/1/2017Royal Bank Of CanadaReiterated RatingBuy$31.00N/AView Rating Details
8/9/2017Oppenheimer Holdings, Inc.Reiterated RatingHoldMediumView Rating Details
7/30/2017Stifel NicolausReiterated RatingBuy$32.00MediumView Rating Details
7/28/2017Cowen and CompanyReiterated RatingBuy$31.00 -> $32.00LowView Rating Details
6/28/2017J P Morgan Chase & CoReiterated RatingOverweight$27.00 -> $31.00LowView Rating Details
6/28/2017Barclays PLCBoost Price TargetOverweight -> Overweight$30.00 -> $31.00LowView Rating Details
6/22/2017Needham & Company LLCBoost Price TargetBuy$30.00 -> $32.00LowView Rating Details
6/21/2017BMO Capital MarketsReiterated RatingBuy$30.00LowView Rating Details
6/16/2017Wells Fargo & CompanyReiterated RatingOutperform$29.50 -> $31.00LowView Rating Details
5/16/2017Goldman Sachs Group IncInitiated CoverageNeutral -> Neutral$28.00LowView Rating Details
4/28/2017Evercore ISIBoost Price TargetOutperform$26.50 -> $28.50LowView Rating Details
4/12/2017GuggenheimReiterated RatingBuyLowView Rating Details
2/23/2017Northland SecuritiesReiterated RatingPositiveN/AView Rating Details
2/5/2017BTIG ResearchReiterated RatingHoldN/AView Rating Details
10/6/2016Citigroup Inc.Boost Price TargetBuy$28.00 -> $29.00N/AView Rating Details
9/1/2016ArgusUpgradeHold -> Buy$23.82 -> $33.00N/AView Rating Details
7/29/2016Credit Suisse GroupReiterated RatingBuyN/AView Rating Details
7/29/2016Leerink SwannReiterated RatingBuyN/AView Rating Details
7/29/2016WedbushBoost Price TargetNeutral$23.00 -> $25.00N/AView Rating Details
7/28/2016Benchmark Co.Boost Price TargetBuy$25.00 -> $31.00N/AView Rating Details
6/21/2016Piper Jaffray CompaniesReiterated RatingOverweight$26.00N/AView Rating Details
3/27/2016Morgan StanleyReiterated RatingOverweight$22.00N/AView Rating Details
3/25/2016Bank of America CorporationReiterated RatingBuy$23.00N/AView Rating Details
3/18/2016Longbow ResearchInitiated CoverageBuyN/AView Rating Details
3/17/2016NomuraInitiated CoverageBuy$22.00N/AView Rating Details
3/12/2016Deutsche Bank AGReiterated RatingHoldN/AView Rating Details
2/25/2016SunTrust Banks, Inc.Initiated CoverageBuy$21.00N/AView Rating Details
1/4/2016Sterne Agee CRTBoost Price TargetBuy$21.00 -> $22.50N/AView Rating Details
(Data available from 9/25/2015 forward)


Earnings History for Boston Scientific Corporation (NYSE:BSX)
Earnings by Quarter for Boston Scientific Corporation (NYSE:BSX)
Earnings History by Quarter for Boston Scientific Corporation (NYSE BSX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
10/24/2017$0.31N/AView Earnings Details
7/27/2017Q2 2017$0.31$0.32$2.21 billion$2.26 billionViewN/AView Earnings Details
4/27/2017Q1 2017$0.30$0.29$2.08 billion$2.16 billionViewN/AView Earnings Details
2/2/2017Q416$0.29$0.30$2.16 billion$2.19 billionViewListenView Earnings Details
10/26/2016Q316$0.27$0.27$2.07 billion$2.11 billionViewListenView Earnings Details
7/28/2016Q216$0.27$0.27$2.05 billion$2.13 billionViewListenView Earnings Details
4/27/2016Q116$0.24$0.28$1.91 billion$1.96 billionViewListenView Earnings Details
2/4/2016Q415$0.25$0.26$2.00 billion$1.98 billionViewListenView Earnings Details
10/28/2015Q315$0.23$0.24$1.86 billion$1.89 billionViewListenView Earnings Details
7/23/2015Q215$0.21$0.22$1.83 billion$1.84 billionViewListenView Earnings Details
4/28/2015Q115$0.21$0.21$1.78 billion$1.77 billionViewListenView Earnings Details
2/4/2015Q414$0.21$0.22$1.91 billion$1.89 billionViewListenView Earnings Details
10/22/2014Q314$0.20$0.20$1.82 billion$1.85 billionViewListenView Earnings Details
7/24/2014Q214$0.20$0.21$1.87 billion$1.87 billionViewListenView Earnings Details
4/29/2014Q114$0.18$0.20$1.80 billion$1.77 billionViewListenView Earnings Details
2/4/2014Q4$0.13$0.21$1.83 billion$1.84 billionViewListenView Earnings Details
10/24/2013Q313$0.09$0.17$1.73 billion$1.74 billionViewListenView Earnings Details
7/25/2013Q2 2013$0.10$0.18$1.78 billion$1.81 billionViewListenView Earnings Details
4/25/2013Q1 2013$0.09$0.16$1.79 billion$1.76 billionViewListenView Earnings Details
1/29/2013Q4 2012$0.11$0.18$1.76 billion$1.82 billionViewListenView Earnings Details
10/18/2012$0.11($0.52)ViewN/AView Earnings Details
7/26/2012$0.08$0.17ViewN/AView Earnings Details
4/19/2012$0.13$0.15ViewN/AView Earnings Details
2/2/2012$0.08$0.07ViewN/AView Earnings Details
10/20/2011$0.09$0.15ViewN/AView Earnings Details
7/28/2011$0.08$0.17ViewN/AView Earnings Details
4/20/2011$0.04$0.01ViewN/AView Earnings Details
2/1/2011$0.09$0.15ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Boston Scientific Corporation (NYSE:BSX)
2017 EPS Consensus Estimate: $1.25
2018 EPS Consensus Estimate: $1.41
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20175$0.29$0.31$0.30
Q2 20175$0.31$0.31$0.31
Q3 20176$0.30$0.32$0.31
Q4 20175$0.32$0.35$0.33
Q1 20182$0.29$0.30$0.30
Q2 20182$0.35$0.36$0.36
Q3 20183$0.35$0.37$0.36
Q4 20182$0.39$0.40$0.40
(Data provided by Zacks Investment Research)


Dividend History for Boston Scientific Corporation (NYSE:BSX)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Boston Scientific Corporation (NYSE:BSX)
Insider Ownership Percentage: 0.74%
Institutional Ownership Percentage: 90.44%
Insider Trades by Quarter for Boston Scientific Corporation (NYSE:BSX)
Institutional Ownership by Quarter for Boston Scientific Corporation (NYSE:BSX)
Insider Trades by Quarter for Boston Scientific Corporation (NYSE:BSX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/1/2017Timothy A PrattEVPSell10,104$27.46$277,455.84View SEC Filing  
8/31/2017Maulik NanavatySVPSell57,031$27.28$1,555,805.68View SEC Filing  
8/30/2017Maulik NanavatySVPSell27,031$27.08$731,999.48View SEC Filing  
8/29/2017Michael P. PhalenEVPSell15,500$26.87$416,485.00View SEC Filing  
8/3/2017Wendy CarruthersSVPSell12,433$26.75$332,582.75View SEC Filing  
8/2/2017John Bradley SorensonSVPSell7,900$26.37$208,323.00View SEC Filing  
8/1/2017Timothy A PrattEVPSell10,000$26.67$266,700.00View SEC Filing  
7/31/2017John Bradley SorensonSVPSell2,100$27.15$57,015.00View SEC Filing  
7/31/2017Michael P. PhalenEVPSell15,500$27.13$420,515.00View SEC Filing  
7/11/2017Daniel J BrennanCFOSell92,158$27.48$2,532,501.84View SEC Filing  
7/3/2017Timothy A PrattEVPSell10,000$27.87$278,700.00View SEC Filing  
6/29/2017Michael P. PhalenEVPSell15,500$28.02$434,310.00View SEC Filing  
6/9/2017David A PierceSVPSell13,562$28.00$379,736.00View SEC Filing  
6/2/2017David A PierceSVPSell2,972$27.70$82,324.40View SEC Filing  
6/1/2017Timothy A PrattEVPSell10,000$27.13$271,300.00View SEC Filing  
5/30/2017Michael P. PhalenEVPSell15,500$27.25$422,375.00View SEC Filing  
5/17/2017Kevin J. BallingerEVPSell28,864$26.14$754,504.96View SEC Filing  
5/1/2017Timothy A PrattEVPSell10,000$26.37$263,700.00View SEC Filing  
4/26/2017David A PierceSVPSell10,250$26.00$266,500.00View SEC Filing  
4/26/2017Michael P. PhalenEVPSell34,773$26.00$904,098.00View SEC Filing  
4/10/2017John Bradley SorensonSVPSell2,950$24.66$72,747.00View SEC Filing  
4/3/2017Timothy A PrattEVPSell10,000$24.87$248,700.00View SEC Filing  
3/29/2017Michael P. PhalenEVPSell79,045$24.55$1,940,554.75View SEC Filing  
3/3/2017David A PierceSVPSell25,012$25.01$625,550.12View SEC Filing  
3/3/2017Timothy A PrattEVPSell23,540$25.01$588,735.40View SEC Filing  
2/27/2017David A PierceSVPSell3,417$24.84$84,878.28View SEC Filing  
2/27/2017Timothy A PrattEVPSell4,832$24.84$120,026.88View SEC Filing  
2/7/2017Keith D DawkinsEVPSell80,783$25.21$2,036,539.43View SEC Filing  
1/9/2017David A PierceSVPSell10,232$22.24$227,559.68View SEC Filing  
1/9/2017Timothy A PrattEVPSell6,195$22.24$137,776.80View SEC Filing  
12/1/2016Timothy A PrattEVPSell26,726$20.48$547,348.48View SEC Filing  
8/11/2016John Bradley SorensonSVPSell2,500$23.90$59,750.00View SEC Filing  
8/1/2016Michael F MahoneyCEOSell44,400$24.44$1,085,136.00View SEC Filing  
8/1/2016Timothy A PrattEVPSell24,000$24.46$587,040.00View SEC Filing  
7/20/2016David A PierceSVPSell2,480$24.03$59,594.40View SEC Filing  
7/20/2016Michael P. PhalenEVPSell35,000$24.03$841,050.00View SEC Filing  
6/1/2016Michael F MahoneyCEOSell100,000$22.69$2,269,000.00View SEC Filing  
6/1/2016Timothy A PrattEVPSell24,229$22.66$549,029.14View SEC Filing  
5/11/2016John Bradley SorensonSVPSell2,800$22.15$62,020.00View SEC Filing  
5/10/2016Keith D DawkinsEVPSell80,000$22.15$1,772,000.00View SEC Filing  
5/6/2016Jeffrey B MirvissSVPSell24,659$21.94$541,018.46View SEC Filing  
5/3/2016Joseph Michael FitzgeraldEVPSell79,960$21.81$1,743,927.60View SEC Filing  
5/2/2016Michael F MahoneyCEOSell100,000$22.12$2,212,000.00View SEC Filing  
5/2/2016Timothy A PrattEVPSell24,000$21.93$526,320.00View SEC Filing  
4/27/2016Kevin J BallingerSVPSell111,807$21.62$2,417,267.34View SEC Filing  
4/27/2016Timothy A PrattEVPSell39,927$21.40$854,437.80View SEC Filing  
4/4/2016Jeffrey B MirvissSVPSell18,422$19.00$350,018.00View SEC Filing  
4/1/2016Michael F MahoneyCEOSell100,000$18.90$1,890,000.00View SEC Filing  
4/1/2016Timothy A PrattEVPSell24,000$18.73$449,520.00View SEC Filing  
3/11/2016Kevin J BallingerSVPSell16,705$18.00$300,690.00View SEC Filing  
3/8/2016Karen PrangeSVPSell14,747$17.27$254,680.69View SEC Filing  
3/2/2016Michael P. PhalenEVPSell10,665$17.17$183,118.05View SEC Filing  
3/1/2016Michael F MahoneyCEOSell100,000$16.96$1,696,000.00View SEC Filing  
3/1/2016Timothy A PrattEVPSell15,068$16.97$255,703.96View SEC Filing  
2/29/2016Kevin J. BallingerSVPSell2,114$17.17$36,297.38View SEC Filing  
2/29/2016Michael P. PhalenEVPSell1,819$17.19$31,268.61View SEC Filing  
2/25/2016Daniel J BrennanCFOSell103,211$17.22$1,777,293.42View SEC Filing  
2/25/2016Kevin J. BallingerSVPSell1,903$17.48$33,264.44View SEC Filing  
2/25/2016Michael P. PhalenEVPSell34,106$17.28$589,351.68View SEC Filing  
2/17/2016Kevin J. BallingerSVPSell7,616$17.37$132,289.92View SEC Filing  
2/12/2016Charles J DockendorffDirectorBuy30,000$16.49$494,700.00View SEC Filing  
2/8/2016Karen PrangeSVPSell6,216$16.05$99,766.80View SEC Filing  
1/8/2016Timothy A PrattEVPSell7,160$17.67$126,517.20View SEC Filing  
1/7/2016Kevin J BallingerSVPSell19,059$17.73$337,916.07View SEC Filing  
1/5/2016Jeffrey B MirvissSVPSell9,953$18.00$179,154.00View SEC Filing  
12/1/2015Timothy A. PrattEVPSell24,000$18.43$442,320.00View SEC Filing  
11/16/2015Ernest MarioDirectorSell125,000$17.63$2,203,750.00View SEC Filing  
11/9/2015John Bradley SorensonSVPSell4,469$18.68$83,480.92View SEC Filing  
11/9/2015Joseph Michael FitzgeraldEVPSell26,220$18.58$487,167.60View SEC Filing  
11/5/2015Timothy A PrattEVPSell19,598$19.00$372,362.00View SEC Filing  
10/28/2015Jeffrey B MirvissSVPSell9,492$18.00$170,856.00View SEC Filing  
10/28/2015Timothy A PrattEVPSell3,500$18.00$63,000.00View SEC Filing  
10/5/2015Timothy A PrattEVPSell3,500$17.34$60,690.00View SEC Filing  
10/1/2015Timothy A. PrattEVPSell17,000$16.33$277,610.00View SEC Filing  
8/21/2015John E AbeleDirectorBuy200,000$16.77$3,354,000.00View SEC Filing  
8/19/2015John E AbeleDirectorBuy200,000$17.48$3,496,000.00View SEC Filing  
8/17/2015John E AbeleDirectorBuy100,000$17.50$1,750,000.00View SEC Filing  
7/7/2015Karen PrangeSVPSell17,456$17.66$308,272.96View SEC Filing  
5/29/2015Maulik NanavatySVPSell71,558$18.52$1,325,254.16View SEC Filing  
5/28/2015Wendy CarruthersSVPSell42,281$17.91$757,252.71View SEC Filing  
5/18/2015Ernest MarioDirectorSell50,000$18.09$904,500.00View SEC Filing  
5/14/2015John E SununuDirectorSell10,000$17.87$178,700.00View SEC Filing  
5/11/2015John Bradley SorensonSVPSell8,735$17.49$152,775.15View SEC Filing  
3/20/2015David A PierceSVPSell18,050$18.00$324,900.00View SEC Filing  
3/20/2015Michael P PhalenEVPSell46,085$17.94$826,764.90View SEC Filing  
3/16/2015Michael P PhalenEVPSell30,022$17.18$515,777.96View SEC Filing  
3/13/2015John Bradley SorensonSVPSell3,830$16.84$64,497.20View SEC Filing  
3/9/2015David A PierceSVPSell2,561$16.54$42,358.94View SEC Filing  
3/3/2015David A PierceSVPSell8,983$16.79$150,824.57View SEC Filing  
3/3/2015Michael P PhalenEVPSell12,768$16.79$214,374.72View SEC Filing  
2/27/2015David A PierceSVPSell19,046$16.80$319,972.80View SEC Filing  
2/27/2015Michael P PhalenEVPSell1,819$16.80$30,559.20View SEC Filing  
2/19/2015David A PierceSVPSell11,958$16.46$196,828.68View SEC Filing  
2/19/2015Michael P PhalenEVPSell13,188$16.44$216,810.72View SEC Filing  
2/10/2015Joseph Michael FitzgeraldEVPSell61,208$14.66$897,309.28View SEC Filing  
2/9/2015David A PierceSVPSell5,000$14.66$73,300.00View SEC Filing  
2/6/2015Kevin J BallingerSVPSell21,408$15.06$322,404.48View SEC Filing  
1/20/2015Michael P PhalenEVPSell10,000$14.54$145,400.00View SEC Filing  
1/8/2015David A PierceSVPSell18,612$14.31$266,337.72View SEC Filing  
1/8/2015Michael P PhalenEVPSell27,589$14.31$394,798.59View SEC Filing  
1/5/2015Michael P PhalenEVPSell10,000$13.75$137,500.00View SEC Filing  
12/10/2014Karen PrangeSVPSell19,753$12.64$249,677.92View SEC Filing  
12/8/2014David A PierceSVPSell5,000$12.90$64,500.00View SEC Filing  
12/1/2014Ernest MarioDirectorSell10,000$12.96$129,600.00View SEC Filing  
11/28/2014Michael F MahoneyCEOBuy11,700$12.89$150,813.00View SEC Filing  
11/10/2014Edward J LudwigDirectorBuy10,000$13.38$133,800.00View SEC Filing  
11/5/2014John E SununuDirectorSell8,997$13.38$120,379.86View SEC Filing  
11/3/2014Ernest MarioDirectorSell10,000$13.30$133,000.00View SEC Filing  
10/8/2014Ernest MarioDirectorSell10,000$12.06$120,600.00View SEC Filing  
9/2/2014Ernest MarioDirectorSell10,000$12.60$126,000.00View SEC Filing  
8/15/2014Michael P PhalenEVPSell11,471$12.58$144,305.18View SEC Filing  
8/1/2014Ernest MarioDirectorSell10,000$12.58$125,800.00View SEC Filing  
7/30/2014David A PierceSVPSell157$12.97$2,036.29View SEC Filing  
7/15/2014Michael P PhalenEVPSell67,500$13.04$880,200.00View SEC Filing  
7/1/2014Ernest MarioDirectorSell10,000$12.95$129,500.00View SEC Filing  
6/16/2014Michael P PhalenEVPSell13,500$13.02$175,770.00View SEC Filing  
6/2/2014Ernest MarioDirectorSell10,000$12.88$128,800.00View SEC Filing  
5/15/2014Michael PhalenEVPSell13,500$12.76$172,260.00View SEC Filing  
5/1/2014Ernest MarioDirectorSell10,000$12.58$125,800.00View SEC Filing  
4/15/2014Michael PhalenEVPSell13,500$13.25$178,875.00View SEC Filing  
4/1/2014Ernest MarioDirectorSell10,000$13.55$135,500.00View SEC Filing  
3/17/2014Michael PhalenEVPSell13,500$13.05$176,175.00View SEC Filing  
3/6/2014David PierceSVPSell5,316$13.44$71,447.04View SEC Filing  
3/6/2014Michael PhalenEVPSell7,281$13.44$97,856.64View SEC Filing  
2/27/2014David PierceSVPSell2,057$13.29$27,337.53View SEC Filing  
2/27/2014Michael PhalenEVPSell3,166$13.29$42,076.14View SEC Filing  
2/21/2014David PierceSVPSell3,199$13.22$42,290.78View SEC Filing  
2/21/2014Michael PhalenEVPSell3,222$13.22$42,594.84View SEC Filing  
2/18/2014Michael PhalenEVPSell13,500$13.30$179,550.00View SEC Filing  
2/13/2014Kristina JohnsonDirectorSell18,000$13.01$234,180.00View SEC Filing  
2/6/2014Ernest MarioDirectorSell17,104$12.80$218,931.20View SEC Filing  
2/3/2014Ernest MarioDirectorSell10,000$13.19$131,900.00View SEC Filing  
1/6/2014Ernest MarioDirectorSell10,000$12.50$125,000.00View SEC Filing  
12/26/2013Ernest MarioDirectorSell10,000$12.06$120,600.00View SEC Filing  
11/26/2013Jeffrey CapelloCFOSell85,106$11.82$1,005,952.92View SEC Filing  
11/11/2013Jeffrey MirvissSVPSell26,000$11.91$309,660.00View SEC Filing  
8/29/2013Jeffrey CapelloCFOSell525,000$10.68$5,607,000.00View SEC Filing  
8/16/2013Joseph Michael FitzgeraldSVPSell9,202$11.02$101,406.04View SEC Filing  
8/14/2013Kevin BallingerSVPSell38,171$11.28$430,568.88View SEC Filing  
5/31/2013Jeffrey B MirvissSVPSell10,941$9.37$102,517.17View SEC Filing  
5/30/2013Wendy CarruthersSVPSell25,001$9.16$229,009.16View SEC Filing  
5/29/2013Nelda J ConnorsDirectorSell24,116$9.17$221,143.72View SEC Filing  
5/6/2013Ernest MarioDirectorBuy30,000$7.76$232,800.00View SEC Filing  
11/13/2012Nj Nicholas JrDirectorBuy20,000$5.28$105,600.00View SEC Filing  
11/9/2012Nj Nicholas JrDirectorBuy25,000$5.17$129,250.00View SEC Filing  
8/6/2012Ernest MarioDirectorBuy32,000$5.29$169,280.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Boston Scientific Corporation (NYSE:BSX)
Latest Headlines for Boston Scientific Corporation (NYSE:BSX)
DateHeadline logoBoston Scientific's Resonate Devices With HeartLogic Heart Failure Diagnostic - Nasdaq - September 25 at 7:59 PM logoETFs with exposure to Boston Scientific Corp. : September 22, 2017 - September 22 at 3:45 PM logoBoston Scientific Corp. :BSX-US: Earnings Analysis: Q2, 2017 By the Numbers : September 21, 2017 - September 21 at 4:35 PM logoZacks: Brokerages Expect Boston Scientific Corporation (BSX) Will Announce Quarterly Sales of $2.20 Billion - September 21 at 9:48 AM logoBoston Scientific Announces Positive Late-Breaking Clinical Trial Data for the HeartLogic™ Heart Failure Diagnostic - September 19 at 4:49 PM logo$0.31 Earnings Per Share Expected for Boston Scientific Corporation (BSX) This Quarter - September 19 at 4:12 AM logoBoston Scientific Corporation (BSX) Receives Consensus Recommendation of "Buy" from Brokerages - September 16 at 12:38 PM logoVeniti strikes distribution agreement with Boston Scientific - September 13 at 5:57 PM logo3 Big Stock Charts for Tuesday: Abbott Laboratories (ABT), Aetna Inc (AET) and Boston Scientific Corporation (BSX) - September 12 at 10:38 AM logoStocks Close Mixed; eBay, These Other 5 Top Stocks Hit Buy Points - September 7 at 5:02 PM logoBoston Scientific Corporation (BSX) Stock Rating Reaffirmed by Jefferies Group LLC - September 7 at 1:34 PM logoBoston Scientific Grows on Innovation, Buyouts Amid Woes - Nasdaq - September 7 at 2:50 AM logoBoston Scientific Grows on Innovation, Buyouts Amid Woes - September 6 at 4:48 PM logoBoston Scientific Is Accelerating Category Leadership Strategy - September 4 at 4:53 PM logoBoston Scientific’s Expansion Plans in a Fast-Growing Market - September 4 at 4:53 PM logoBoston Scientific’s Updated 2017 Guidance - September 4 at 4:53 PM logo$2.20 Billion in Sales Expected for Boston Scientific Corporation (BSX) This Quarter - September 2 at 1:26 PM logoRoyal Bank Of Canada Reaffirms Buy Rating for Boston Scientific Corporation (BSX) - September 2 at 7:34 AM logoBoston Scientific Corporation (BSX) EVP Sells $277,455.84 in Stock - September 1 at 8:04 PM logoMaulik Nanavaty Sells 27,031 Shares of Boston Scientific Corporation (BSX) Stock - September 1 at 7:40 PM logoMaulik Nanavaty Sells 57,031 Shares of Boston Scientific Corporation (BSX) Stock - September 1 at 7:22 PM logoBoston Scientific Corp. breached its 50 day moving average in a Bullish Manner : BSX-US : September 1, 2017 - September 1 at 5:02 PM logoHow Can BSX Improve Its Profitability Going Forward? - September 1 at 5:02 PM logoBoston Scientific Corporation (BSX) EVP Sells $416,485.00 in Stock - August 30 at 7:36 PM logo​Boston Scientific receives award at the Pentagon for support of veterans - Boston Business Journal - August 29 at 10:13 PM logoBoston Scientific To Participate In Morgan Stanley Global Healthcare Conference - August 28 at 4:45 PM logoBoston Scientific Corporation (BSX) Lowered to Sell at BidaskClub - August 26 at 6:40 PM logo[$$] Funding Snapshot: Women's Health Care Provider Channel Medsystems Receives $14.1 Million Series C-1 - August 23 at 4:57 PM logo[$$] Medical Tech Bounces Back in Emerging Markets - August 23 at 4:57 PM logoBoston Scientific Corporation (BSX) Receives Consensus Rating of "Buy" from Analysts - August 22 at 12:50 PM logoBoston Scientific To Participate In Wells Fargo 2017 Healthcare Conference - August 21 at 4:44 PM logoBoston Scientific Corporation (BSX) Lifted to "Hold" at BidaskClub - August 19 at 7:46 PM logoZacks: Brokerages Expect Boston Scientific Corporation (BSX) Will Post Quarterly Sales of $2.20 Billion - August 15 at 1:40 PM logoHealth care divide leaves tax on path to reinstatement - August 13 at 11:01 AM logo Brokerages Expect Boston Scientific Corporation (BSX) to Announce $0.31 EPS - August 13 at 4:14 AM logoIHS Markit Score Update: Drop in demand for ETFs holding Boston Scientific Corp is a negative sign for its shares - August 11 at 4:02 AM logoSee what the IHS Markit Score report has to say about Boston Scientific Corp. - August 10 at 2:58 AM logoBoston Scientific Corp (BSX) Presents at Canaccord Genuity Growth Broker Conference (Transcript) - Seeking Alpha - August 9 at 9:58 PM logoBoston Scientific Corporation (NYSE:BSX) Stock Rating Reaffirmed by Oppenheimer Holdings, Inc. - August 9 at 6:46 PM logoBoston Scientific Corp. – Value Analysis (NYSE:BSX) : August 8, 2017 - August 8 at 9:36 PM logoBRIEF-Boston Scientific Corp says entered into a $2.25 bln senior unsecured credit facility- SEC Filing - August 7 at 5:18 PM logoBRIEF-Boston Scientific Corp says entered into a $2.25 bln senior unsecured credit facility- SEC Filing - August 7 at 5:18 PM logoNotice of REVA Medical Briefing Call - August 7 at 1:21 PM logoInsider Selling: Boston Scientific Corporation (NYSE:BSX) SVP Sells 7,900 Shares of Stock - August 4 at 8:40 PM logoWendy Carruthers Sells 12,433 Shares of Boston Scientific Corporation (BSX) Stock - August 4 at 8:22 PM logoBoston Scientific’s Distribution Option Lapses - August 3 at 11:19 PM logo10-Q: BOSTON SCIENTIFIC CORP - August 3 at 6:14 PM logoInsider Selling: Boston Scientific Corporation (BSX) EVP Sells 10,000 Shares of Stock - August 2 at 8:34 PM logoEquities Analysts Offer Predictions for Boston Scientific Corporation's Q2 2018 Earnings (NYSE:BSX) - August 2 at 3:28 PM logoBoston Scientific Corporation (NYSE:BSX) Receives Buy Rating from UBS AG - August 1 at 10:28 PM



Boston Scientific Corporation (BSX) Chart for Monday, September, 25, 2017

This page was last updated on 9/25/2017 by Staff